ImCheck Therapeutics logo

ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

57 employees · est. 2015 · Marseille, France

VS
Innate Pharma logo

Innate Pharma

196 employees · est. 1999 · Marseille, France

Innate Pharma is the older company (2015 vs 1999).

Side-by-Side Comparison

ImCheck Therapeutics Innate Pharma
Founded
2015 1999 older
Headquarters
Marseille, France Marseille, France
Employees
57 196
Industry
Biopharma, Biotechnology, Health Care Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Grant Post Ipo Secondary
Total Funding
$193.11M $276.10M
Funding Rounds
7 8
Services
development of immunotherapeutic antibodies, immune system modulation research, clinical research in AML patients Not tracked yet
Target Customers
patients with cancer, patients with infectious diseases, patients with autoimmune diseases Not tracked yet
Taxonomy
Immunotherapy, Oncology, Antibody Therapeutics, Cancer Treatment, Immune Checkpoint Inhibitors, Autoimmune Diseases, Immunomodulators, Biopharmaceuticals, Drug Development, Precision Medicine Biotech Company, Oncology-focused, Therapeutic Antibodies, Immune System, Cancer Treatment, NK Cell Biology, Tumor Microenvironment, Antibody Engineering, Global Presence, Euronext Paris, Nasdaq, Clinical-stage, Immunotherapy, Pipeline Of Antibodies, Strategic Alliances
Website
imchecktherapeutics.com innate-pharma.com
ImCheck Therapeutics logo

About ImCheck Therapeutics

ImCheck Therapeutics, with the slogan "Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic," is focused on designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. Their lead clinica...

Innate Pharma logo

About Innate Pharma

Innate Pharma is a global, clinical-stage oncology-focused biotech company founded in 1999 and headquartered in France. The company is dedicated to improving treatment and clinical outcomes for cancer patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Phar...

We will tell you when either one moves

BounceWatch watches ImCheck Therapeutics and Innate Pharma for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ImCheck Therapeutics and Innate Pharma — by email.

Frequently Asked Questions

ImCheck Therapeutics — Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic. Innate Pharma. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ImCheck Therapeutics has raised $193.11M while Innate Pharma has raised $276.10M.
ImCheck Therapeutics and Innate Pharma operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ImCheck Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at ImCheck Therapeutics on 11 Jun 2025, and Innate Pharma on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy